Highlights Lipidor AB

Equities

LIPI

SE0012558617

Market Closed - Nasdaq Stockholm Other stock markets 11:18:41 2024-04-29 am EDT			5-day change	1st Jan Change
0.25 ^SEK	+6.38%		+6.38%	-50.40%

Mar. 21	Lipidor AB Announces Approval for Start of Phase III Clinical Trial of Psoriasis Candidate AKP02G2	CI
Feb. 28	Lipidor AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lipidor AB Announces Approval for Start of Phase III Clinical Trial of Psoriasis Candidate AKP02G2	Mar. 21	CI
Lipidor AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 28	CI
Lipidor Applies to the Indian Medical Products Agency to Start A Phase III study of AKP02G2	Dec. 20	CI
Lipidor AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 22	CI
Lipidor AB Files New Patent Application with the European Patent Office	23-10-27	CI
Lipidor, Relife Adds Asia Pacific to Psoriasis Treatment License Deal	23-10-18	MT
Lipidor AB Extends and Expands Cooperation with Relife	23-10-18	CI
Lipidor AB Signs Agreement with Cliantha Research to Conduct A Phase III Study with the Drug Candidate Akp02g2, for the Treatment of Psoriasis	23-09-20	CI
Lipidor AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-23	CI
Lipidor AB Confirms Clinical Plan for New Version of Akp02	23-06-22	CI
Lipidor AB Updates on Development of AKP02	23-05-26	CI
Lipidor AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Lipidor AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-22	CI
Lipidor AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-22	CI
Lipidor AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-23	CI
Lipidor AB Provides Update Following Outcome of Phase Iii Study of Psoriasis Candidate Akp02	22-11-15	CI
Lipidor AB Announces Results from the Its Clinical Phase III Study of AKP02 for Psoriasis	22-10-28	CI
Lipidor Updates on Phase III Clinical Study of Psoriasis Candidate AKP02	22-09-29	CI
Lipidor appoints new CFO Charlotta Ekman	22-08-25	AQ
Lipidor AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Lipidor AB

Equities

LIPI

SE0012558617

Highlights

Filters